TITLE PAGE

1

- 2 Title: Neurofilament light and glial fibrillary acidic protein in mood and anxiety disorders: A
- 3 systematic review and meta-analysis

4 **Authors (incl order)**

| Full name | Highest | Affiliation | Email address |
|--------------------|----------------------------------|---|---|
| Matthew JY | academic degree MBBS, | Neuropsychiatry Centre, Royal | Matthew.kang1@unimelb.edu.au |
| Kang | FRANZCP | Melbourne Hospital | Watthew.kang1 & uninclo.edu.au |
| | | Department of Psychiatry, University of Melbourne | |
| Jasleen Grewal | MBBS | Alfred Mental and Addiction Health, Alfred Health | Jas.grewal@alfred.org.au |
| | | Neuropsychiatry Centre, Royal Melbourne Hospital | |
| Dhamidhu Eratne | MBChB, FRANZCP | Neuropsychiatry Centre, Royal Melbourne Hospital Department of Psychiatry, University of Melbourne | deratne@unimelb.edu.au ORCiD: 0000-0002-3226-7645 |
| Charles Malpas | PhD | Melbourne School of Psychological Sciences, University of Melbourne Department of Medicine, Royal Melbourne Hospital, University of Melbourne | charles.malpas@unimelb.edu.au |
| Wei-Hsuan Chiu | BBiomed(Hons), GDipPsych(Adv) | The Neuropsychiatry Centre, The Royal Melbourne Hospital Department of Psychiatry, The University of Melbourne | whchiu@student.unimelb.edu.au ORCiD: 0000-0002-5066-2999 |
| Kasper Katisko | MD, PhD | Institute of Clinical Medicine – Neurology, University of Eastern Finland, Kuopio, Finland | kasper.katisko@uef.fi |
| Eino Solje | MD, PhD | Institute of Clinical Medicine – Neurology, University of Eastern Finland, Kuopio, Finland | eino.solje@uef.fi |

| | | Neuro Center – Neurology, | |
|-------------|-------------|-------------------------------|--------------------------------------|
| | | Kuopio University Hospital, | |
| | | Kuopio, Finland | |
| Alexander F | MD, PhD | Department of Clinical | alexander.frizell_santillo@med.lu.se |
| Santillo | | Sciences, Clinical Memory | |
| 0000-0001- | | Research Unit, Faculty of | |
| 9717-0820 | | Medicine, Lund University, | |
| | | Malmö, Sweden | |
| Philip B. | MBBS, MD | Discipline of Psychiatry & | phil.mitchell@unsw.edu.au |
| Mitchell | | Mental Health, Faculty of | |
| | | Medicine and Health, UNSW, | |
| | | Sydney | |
| Malcolm | MD, | Ramsay Clinic Albert Road & | mhopwood@unimelb.edu.au |
| Hopwood | FRANZCPsych | Department of Psychiatry, | |
| _ | | University of Melbourne | |
| Dennis | MBBS, | Neuropsychiatry Centre, Royal | Dennis.Velakoulis@mh.org.au |
| Velakoulis | DMedSci | Melbourne Hospital | _ |
| | | _ | |
| | | Department of Psychiatry, | |
| | | University of Melbourne | |

6 Corresponding Author

7 Dr. Matthew JY Kang

5

- 8 The Royal Melbourne Hospital Mental Health Services & Neuropsychiatry Centre
- 9 The RMH Elizabeth Street
- 10 635 Elizabeth Street | Melbourne 3000
- 11 P: 03 9138 2850 | F: 03 7024 7004 | M: 0437 631 101
- 12 Matthew.Kang@mh.org.au | thermh.org.au
- Word count: 2998 words

14 Funding and sponsors

- 15 The MiND Study is generously funded from the following bodies:
- 2020-2024 NHMRC Ideas Grant GNT1185180: The Markers in Neuropsychiatric Disorders
- 17 study.
- 18 MRFF
- Ramsay Health Research Foundation Translation Challenge (2023-2024)

20 Matthew Kang is supported by the Research Training Program Scholarship (stipend) from the 21 Department of Psychiatry, University of Melbourne with contributions from the Australian 22 Commonwealth Government and the Ramsay Health Research Foundation Translation 23 Challenge. 24 The funders had no role in the design or conduct of this study. 25 **Conflicts of interest:** None from MK. PBM has received remuneration from Janssen (Australia) 26 for advisory board membership and lectures in the last 3 years. 27 28 Acknowledgements 29 We would like to thank Dr Mu-Hong Chen, Dr Leila Simani, and Dr Wen-Yin Chen for their 30 assistance in providing their published data separately to be included in the meta-analysis. We 31 are also grateful for the correspondence from the following researchers who assisted us in 32 clarifying questions about their published data: Dr Anja Fernqvist, Dr Sterre de Boer, Dr 33 Naghmeh Nikkheslat, Prof Carmine Pariante, Dr. Pedro J. Serrano Castro, Dr Johanna 34 Wallensten, Dr. Carol Van Hulle, Dr Mark Miller, Dr Daniel Alcolea, Dr. Suzanne Schindler, 35 and Dr. Andrew Aschenbrenner.

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Abstract Background: Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are biomarkers of neuronal injury measurable in cerebrospinal fluid (CSF) and blood. Despite their potential as diagnostic tests for neurodegenerative disorders, it is unclear how they behave in mood and anxiety disorders. We conducted a systematic review and meta-analysis to investigate whether NfL and GFAP concentrations were altered in adults with mood and anxiety disorders compared to healthy controls. Methods: The study was prospectively registered on PROSPERO (CRD42023434617). We followed the PRISMA guidelines, searched PubMed, Web of Science, PsycINFO, MEDLINE and Embase up to the 31/05/2023, and assessed relevant studies and their risk of bias. The primary outcome was the standardised mean difference (SMD) and 95% confidence interval (95% CI) of NfL and GFAP concentrations, which was pooled using a random-effects model adopting the restricted maximum likelihood estimator. **Results:** Twenty-one studies met inclusion criteria, comprising of 2327 individuals (695 major depression, 502 bipolar disorder, and 1130 controls). When we compared people with major depression and controls, there was no difference in NfL (SMD = 0.29; 95% CI: -0.10, 0.68) nor GFAP (SMD = 0.47; 95% CI: -0.74, 1.68). In people with bipolar disorder, NfL was significantly elevated compared to controls (SMD = 0.58; 95% CI: 0.16, 0.99). However, the subgroup analysis including more sensitive assay kits (blood Simoa and CSF ELISA), found no significant difference (SMD = 0.40; 95% CI: -0.04, 0.85). Only one study studied GFAP in bipolar disorder. No studies explored NfL nor GFAP concentrations in anxiety disorders. **Discussion:** We found that NfL and GFAP concentrations were not elevated in depression. In bipolar disorder, NfL concentration was elevated, though not in the sensitivity analysis. Our study informs clinicians about how to interpret these emerging biomarkers in determining whether a person's symptoms are caused by a neurodegenerative or mood disorder.

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Introduction Recent developments in blood and cerebrospinal fluid (CSF) biomarkers in neurological conditions have offered exciting prospects for enhancing diagnostic assessments. Neurofilament light chain (NfL), a cytoskeletal protein of neurons, has emerged as a sensitive biomarker for assessing neuronal injury (1). Neurodegenerative processes lead to the release of NfL into the CSF, which subsequently pass through to the bloodstream at lower concentrations (2). Although initial studies were limited to measuring NfL in CSF, technological advances have facilitated precise quantification of NfL in blood (3). In particular, blood NfL measured using singlemolecule array digital immunoassay (Simoa) correlate well with CSF NfL (4). Numerous studies have shown that NfL, in both CSF and blood, is a valuable marker for diagnosing, assessing disease severity, and predicting prognosis in a diverse range of neurodegenerative conditions, including Alzheimer's disease and frontotemporal lobar degeneration (5–7). NfL can also distinguish neurodegenerative disorders from primary psychiatric disorders within memory clinics and neuropsychiatry services (8–10). More recently, glial fibrillary acidic protein (GFAP), a component of glial cell cytoskeleton, has emerged as a sensitive measure of astrogliosis and neuroinflammation, demonstrating superior prognostic accuracy to NfL in multiple sclerosis (11,12). Given the potential clinical utility of these biomarkers in determining whether an individual's undifferentiated presentation with psychiatric, cognitive and/or neurological symptoms is due to a neurological or a psychiatric cause, it is crucial to understand how NfL or GFAP behave in primary mood or anxiety disorders. If NfL and GFAP levels remain within normal ranges in primary mood and anxiety disorders, which are the two most prevalent mental disorders (13), such findings would support the use of these biomarkers in distinguishing neurodegenerative conditions at diagnostic assessments. Conversely, should they be elevated in primary mood and anxiety disorders, this may provide insights into their neurobiological underpinnings. One of the earliest investigations into NfL and GFAP in psychiatric disorders involved a cohort of elderly women who remained dementia-free during a 10-year follow-up period (14). Those with major depression exhibited significantly higher concentrations of baseline CSF NfL compared to the rest of the group (major depression mean: 427 ± 186 vs control mean: 277 ± 186

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

ng/L), whilst there was no difference in the GFAP concentrations (major depression mean: 946 \pm 196 vs control: 887 ± 308 ng/L). Subsequent studies comparing blood NfL and GFAP in mood disorders to healthy controls have yielded mixed findings, either finding elevated concentrations in mood disorders (15–17), or no difference (6,18). More recent studies have examined the relationship between NfL or GFAP with clinical outcomes in mood disorders. The concentration of GFAP was higher in people with major depression and correlated with the severity of depressive symptoms (17). NfL was found to be negatively correlated with cognitive processing speed in people with major depression compared to healthy controls (19). Several theories have been proposed to explain why NfL or GFAP may be elevated in mood disorders, including astroglia dysfunction (17), vascular pathology (14), and neuroinflammatory processes (20). Given these conflicting findings in this area of major clinical and scientific importance, we have undertaken a systematic review and meta-analysis of studies investigating NfL and GFAP concentrations in people with mood (depression and bipolar disorder) and anxiety disorders compared to healthy controls. Secondly, we sought to identify any associations between the severity of mood and anxiety disorders with NfL and GFAP. **Methods** This systematic review was developed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (21). The protocol was prospectively registered with PROSPERO (CRD42023434617). Eligibility criteria All eligible studies met the following criteria: (1) adult patients diagnosed with either mood (depression and bipolar disorder) or anxiety disorder according to DSM or ICD (22–25); and (2) measured NfL or GFAP in plasma, serum or CSF measured by Simoa, electrochemiluminescence method (ECL) or enzyme linked immunosorbent assay (ELISA). Case-series, meeting abstracts, reviews and meta-analyses were excluded. For articles with overlapped samples, only the report with largest sample size was included.

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

Exclusions criteria were: (1) mood or anxiety disorders due to general medical conditions including dementia and stroke, and (2) co-morbid neurological disorders including multiple sclerosis and dementia. **Search strategy** Electronic searches were conducted via the Web of Science, PubMed, MEDLINE(OVID), Embase and PsycINFO from the inception of the databases through to 31st May 2023. The search terms included ("neurofilament light" OR "NfL") AND ("glial fibrillary acidic protein" OR "GFAP") AND ("depressi*" OR "bipolar*" OR "anxiet*" OR "mood disorder*"). Studies were required to be in English. We have described our full search strategy in the supplementary file. **Study Selection and Data Collection** We used Cochrane's Covidence, a web-based systematic review manager, for study selection and quality analysis. One investigator (MK) screened the title and abstracts. Two investigators (MK and JG) independently reviewed the main reports and supplementary materials for their eligibility. We resolved discrepancies by consensus and involved a third senior investigator (MH) when required. The primary outcome was the mean difference of NfL and GFAP in people with mood and anxiety disorders. The mean and standard deviation (SD) of NfL and GFAP was collected in the different cohorts. If this was not available, authors were contacted for the data. If the authors did not respond, the following methods were used to convert the data according to Cochrane Handbook guidelines (26): 1) median, interquartile ranges and minimum/maximum values were converted using an estimation formula (27,28), 2) mean and SD of subgroups (i.e. male and female) were combined using Cochrane's formula (29), and 3) studies that only presented the results in plots were estimated using WebPlotDigitzer (30). Our secondary outcomes were as follows: 1) mood state and severity (measured by a standardised rating scale), 2) duration of mood/anxiety disorder, and 3) cognitive impairment

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

(measured by a standardised rating scale). We also collected known covariates of NfL and GFAP if they were reported, including age and weight (31). **Quality of individual studies** Two investigators (MK and JG) independently assessed the quality of included studies using the Newcastle-Ottawa Scale (NOS) quality assessment tool (32). NOS contains a total of 8 small items, and evaluates three aspects: selection, comparability and outcome. Studies were classified as "poor quality" (0-2 points), "average quality" (3-5 points), and "good or high quality" (6-9 points). **Statistical analysis** All statistical analyses were performed using R version 4.2.2 (2022-10-31) and the meta package (33). Meta-analyses were separately conducted for individual psychiatric diagnoses (i.e. major depression and bipolar disorder). For each diagnosis, we calculated standardised mean differences (SMDs) of each biomarker (NfL and GFAP) between psychiatric disorders and controls to be able to pool the different types of assay kits. Of note, Random effects metaanalysis models, rather than fixed effects models, were selected a priori based on the theoretical absence of a consistent 'true effect' across the studies. The restricted maximum likelihood estimator was adopted. Ninety-five percent confidence intervals (95% CI) and prediction intervals (PI) were calculated and visualised using forest plots. A PI quantifies the likely range in which a new study's effect size will fall into, assuming that this future study is of a similar nature to those meta-analysed. We assumed a two-sided P < 0.05 to indicate statistical significance. Where there were a sufficient number of studies, sensitivity analyses were performed to ensure any findings were consistent with the main analyses: type of biomarker analysis (i.e. CSF ELISA and serum/plasma Simoa; blood Simoa) and studies that used age-matched controls. We intended to analyse further subgroups including duration of psychiatric illness and age at diagnosis, however there was an insufficient number of studies. We performed meta regression on the severity of mood symptoms as measured by the scales used in the study (i.e. Hamilton's Depression Rating Scale; HDRS and Montgomery-Asberg

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

Depression Rating Scale; MADRS). We could not perform other meta regression analyses including variables such as cognition, duration of psychiatric illness and number of mood disorder episodes due to the limited numbers of studies. As a post-hoc analysis to include studies (all of which used Simoa assay kits) that did not have any control groups, we used a robust mixed-means model to compare the mean concentration of NfL and GFAP between cases (depression or bipolar) and controls. We assessed for publication bias using funnel plots of the effect sizes of mood disorders for NfL and GFAP. We performed meta-analyses only where there were at least five studies to ensure acceptable statistical power to make an inference. I² and tau² statistics were used to quantify between-study heterogeneity in the meta-analyses. **Results Study selection** The systematic search identified 2,890 unique studies, of which 110 were selected for full-text review. Twenty-one studies met our inclusion criteria for the meta-analysis, as shown in Figure 1. Twelve studies investigated major depression, five bipolar disorder, four reported data on both, and no studies reported on other types of mood disorders nor anxiety disorders. The main reason that some full-text articles were excluded was due to studies either not reporting or collecting individual psychiatric diagnoses. A number of studies used a less rigorous process to collect diagnoses (self-report, file review and diagnosis based on a cut-off score from a mood rating scale) (34). Four studies had an insufficient sample size (n<10) (9,35,36). Some studies used indirect measures of NfL and GFAP, including extracellular vesicles, mRNA, IgG autoantibodies and urine (37–40). **Study characteristics** Final sample data were obtained for 2327 individuals, of which 695 had major depression, 502 bipolar disorder, and 1130 healthy controls. Two studies (41,42) did not have a healthy control group, so were only included in the additional mixed-model meta-analyses. Seventeen studies

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

analysed blood samples, three used CSF, and Knorr et al's study (16) investigated both CSF and blood. The majority of the studies (75%) were published after 2020, reflecting the relatively recent availability of Simoa and ELISA technology to measure NfL and GFAP in blood. (Tables 1-2) Although Ashton et al. (2021) reported that the sample size of their control (cognitively unimpaired and CSF amyloid-β negative) and depression groups were 130 and 37 respectively, this conflicted with their supplementary data source table that reported 115 and 51 values respectively. We chose to perform the meta-analysis with the latter values, as they matched the sex proportions reported in their main table. Bavato et al. (2021) drew on 295 healthy controls and referenced their earlier work (Barro et al., 2018, n=258) for the characteristics of the healthy controls, which is included in this meta-analysis instead. **Quality of studies** The quality of studies was considered at least moderate across studies. The area of low quality was in the domain of comparability due to the inequalities in age and sex between study groups, as summarised in the supplementary eTable 1. **Synthesis of results** Major depression Neurofilament light chain All studies (Figure 2a): There was no significant difference in the concentration of NfL in people with major depression compared to healthy controls (SMD = 0.29; 95% CI: -0.10, 0.68). The prediction interval for this pooled mean difference was very wide (PI: -1.11, 1.69) with significant heterogeneity ($I^2 = 90\%$; tau² = 0.37). A regression-based Egger's test did not show any evidence of small study effects (p-value = 0.35) though on visual inspection of the funnel plot (supplementary eFigure 1), Ashton et al's study's was an outlier (6). This study had a significant age difference between the depression and control groups (mean difference 31.7 years). In the subgroup analysis of studies that included age-matched controls (Figure 2b), NfL was significantly higher in major depression, though with a wide PI (SMD = 0.44; 95% CI: 0.11,

251 0.77; PI: -0.61, 1.50). The subgroup analysis model which only included data using CSF 252 **ELISA** and blood Simoa (Figure 2c), which are more accurate measures of NfL (2,4), found no 253 significant difference (SMD = -0.03, 95% CI: -0.53, 0.47). The heterogeneity for both subgroup 254 analysis models were high ($I^2 = 79\%$, tau² = 0.17 and $I^2 = 57\%$, tau² = 0.07 respectively). 255 Similarly, the subgroup analysis model including six age-matched studies that used CSF ELISA 256 and Simoa also found no significant difference (SMD = 0.11 95% CI: -0.32, 0.55). 257 258 A random-effects meta-regression model which included all NfL studies suggested that mood 259 severity did not influence NfL. In the subgroup mixed-model mean analysis of studies that only 260 used blood Simoa, we found no significant difference in NfL levels. 261 262 Glial fibrillary acidic protein 263 GFAP (Figure 2d) was not significantly different between people with major depression and healthy controls (SMD = 0.47; 95% CI: -0.74, 1.68; PI: -3.09, 4.03), with significant 264 heterogeneity between the studies ($I^2 = 92\%$, $tau^2 = 0.53$). There was insufficient data to perform 265 266 additional meta-regressions including cognition and GFAP. 267 268 Bipolar disorder 269 Neurofilament light chain 270 All studies (Figure 3a): The mean concentration of NfL in people with bipolar disorder was 271 significantly higher than healthy control (SMD = 0.58; 95% CI: 0.16, 0.99). However, the 272 prediction interval for this pooled mean difference was wide (PI: -0.67, 1.82) with significant 273 heterogeneity ($I^2 = 84.0\%$, tau² = 0.24). As Knorr et al's study (2022) reported both CSF ELISA 274 and plasma Simoa samples, we performed a sensitivity analysis where we excluded the Simoa 275 dataset, which found NfL was still significantly higher in bipolar disorder compared to healthy 276 controls (SMD = 0.62; 95% CI: 0.14, 1.09), There was no asymmetry on the funnel plot 277 (supplementary eFigure 1), and we could not use Egger's test due to insufficient number of 278 studies. 279 The subgroup analysis model with age-matched studies (Figure 3b) demonstrated significantly 280 higher NfL in bipolar disorder (SMD = 0.50; 95% CI: 0.06, 0.94; PI: -0.74, 1.74). For the

subgroup analysis including only CSF ELISA and blood Simoa studies (Figure 3c), there was

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

no significant difference in the mean concentration of NfL between bipolar disorder and healthy controls (SMD = 0.40; 95% CI: -0.04, 0.85) with a wide prediction interval (PI: -0.80, 1.61). Both models were heterogenous ($I^2 = 82.0\%$, tau² = 0.22 and $I^2 = 81.8\%$, tau² = 0.18 respectively). The subgroup analysis including six age-matched studies which used CSF ELISA and Simoa also found no significant difference in mean NfL between bipolar disorder and healthy controls. (SMD = 0.27 95% CI: -0.12, 0.65). We performed a subgroup mixed-model mean analysis of blood Simoa studies which showed no difference in NfL concentrations. Glial fibrillary acidic protein Only one study (17) studied GFAP in people with bipolar disorder (n=11), which found GFAP concentrations were similar in bipolar disorder compared to healthy controls (125 \pm 50 vs 147 \pm 61 pg/mL). **Discussion** Our systematic review found that NfL and GFAP concentrations were not elevated in people with major depression compared to healthy controls. NfL was elevated in people with bipolar disorder, though the difference was no longer significant with subgroup analysis using more sensitive assay kits (CSF ELISA and blood Simoa). We identified no studies examining NfL or GFAP in people with anxiety disorders. To the best of our knowledge, this is the most comprehensive systematic review of these biomarkers in people with primary mood and anxiety disorders. Our findings align with the existing literature supporting the use of these biomarkers in the differentiation between mood disorders and neurodegenerative disorders (2,5,6). The complex relationship between mood disorders and neurodegenerative disorders, which can present with overlapping symptoms or co-occur, necessitates careful assessment. These findings provide reassurance to clinicians that people with primary mood disorders are unlikely to have very elevated concentrations of NfL and GFAP, as seen in the majority of neurodegenerative disorders where there often is marked elevation (for example, 1.86-fold in Alzheimer's disease, 3.91-fold in frontotemporal dementia; 44,45).

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

In individuals with mood disorders, we noted variable instances where NfL concentration was elevated compared to healthy controls, indicating that neuronal injury or neuroinflammation might be present in a specific subset. The limitations of the available data, including detailed clinical and treatment information, prevented us from being able to investigate this further. We plan to conduct a 'mega-analysis' by pooling the raw data from the studies included. This approach will enable us to perform statistical adjustments for known covariates including as age, sex and weight/BMI, which were not possible in the meta-analysis. Moreover, identifying specific clusters of symptomatology that correlate with NfL/GFAP may offer valuable insights into the neurodegenerative and neuroinflammatory phenotypes within mood disorders. In turn, opens a new paradigm of diagnosis and treatment for these patients based on biomarker data as well as reported symptoms, in line with the RDOC Framework (56). Despite the widespread prevalence and burden of anxiety disorders (13), no prior research has explored NfL and GFAP in individuals with primary anxiety disorders. This is an important gap in the literature that this systematic review has identified for the use of NfL and GFAP in clinical practice. The review process faced several limitations. The evidence was constrained by the quality and heterogeneity of included studies. Controls were not consistently age- and sex-matched (6,18), and some studies lacked control subjects (41,42,51). The limited number of studies and data precluded adequate adjustment for known covariates of NfL and GFAP, such as age, sex, weight/BMI, and renal function (2). This also hindered exploration of factors like mood disorder states (euthymic vs depressed) or effects of psychotropic medications (46). Furthermore, to harmonise the dataset, some of the meta-analyses relied on estimates derived from raw data, which may have introduced potential inaccuracies in the true estimates. Despite our attempts to include as many articles as possible by searching important databases, grey literature, as well as snowballing for other relevant articles, it is possible that some studies may have been inadvertently omitted.

Our primary analysis indicated that NfL and GFAP levels were not significantly elevated in major depression, while in bipolar disorder, NfL was elevated compared to controls. Subgroup analysis using more sensitive assays revealed no notable differences. These findings suggest that NfL and GFAP elevations in mood disorders are minimal, contrasting with the large elevations in neurodegenerative disorders. This supports the use of these biomarkers in clinical settings to distinguish psychiatric from neurodegenerative causes. The practicality of blood-based biomarker measurements offers valuable diagnostic insights to answer the common clinical question faced by patients, carers and clinicians.

References

- Gaetani L, Blennow K, Calabresi P, Filippo MD, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019
 Aug 1;90(8):870–81.
- Arslan B, Zetterberg H. Neurofilament light chain as neuronal injury marker what is needed to facilitate implementation in clinical laboratory practice? Clinical Chemistry and Laboratory Medicine (CCLM). 2023 Jun 27;61(7):1140–9.
- 36. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology. 2018 Oct;14(10):577–89.
- Alagaratnam J, von Widekind S, De Francesco D, Underwood J, Edison P, Winston A, et al.
 Correlation between CSF and blood neurofilament light chain protein: a systematic review
 and meta-analysis. BMJ Neurol Open. 2021 Jun 16;3(1):e000143.
- 5. Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. The Lancet Neurology. 2022 Mar;21(3):246–57.
- 371 6. Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021 Jun 7;12(1):3400.
- Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, et al. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.
 Alzheimer's & Dementia. 2022;18(11):2218–33.
- Eratne D, Kang M, Malpas C, Simpson-Yap S, Lewis C, Dang C, et al. Plasma
 neurofilament light in behavioural variant frontotemporal dementia compared to mood and
 psychotic disorders. Aust N Z J Psychiatry. 2023 Jul 21;00048674231187312.
- Kang MJ, Eratne D, Dobson H, Malpas CB, Keem M, Lewis C, et al. Cerebrospinal fluid
 neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and
 neurodegenerative disorders. Acta Neuropsychiatrica. 2023 Apr 28;1–36.
- 384 10. Willemse EAJ, Scheltens P, Teunissen CE, Vijverberg EGB. A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alz Res Therapy. 2021 Dec;13(1):101.
- 387 11. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, et al. Blood GFAP as 388 an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022 389 Mar;18(3):158–72.

- 390 12. Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, et al.
- 391 Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a
- 392 Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurology. 2023 Mar
- 393 1;80(3):287–97.
- 394 13. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12
- mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the
- Global Burden of Disease Study 2019. The Lancet Psychiatry. 2022 Feb 1;9(2):137–50.
- 397 14. Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, et al. Is there a
- 398 CSF biomarker profile related to depression in elderly women? Psychiatry Research.
- 399 2010;176(2-3):174-8.
- 400 15. Hviid CVB, Benros ME, Krogh J, Nordentoft M, Christensen SH. Serum glial fibrillary
- acidic protein and neurofilament light chain in treatment-naïve patients with unipolar
- depression. Journal of Affective Disorders. 2023 Oct 1;338:341–8.
- 403 16. Knorr U, Simonsen AH, Jensen CS, Zetterberg H, Blennow K, Akhøj M, et al. Alzheimer's
- disease related biomarkers in bipolar disorder A longitudinal one-year case-control study. J
- 405 Affect Disord. 2022 Jan 15;297:623–33.
- 406 17. Steinacker P, Al Shweiki MR, Oeckl P, Graf H, Ludolph AC, Schönfeldt-Lecuona C, et al.
- Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of
- 408 major depressive disorder. Journal of Psychiatric Research. 2021 Dec;144:54–8.
- 409 18. Huang MC, Chen CH, Liu TH, Chung AN, Liu YL, Quednow BB, et al. Comorbidity of
- ketamine dependence with major depressive disorder increases the vulnerability to
- neuroaxonal pathology. Journal of Psychiatric Research. 2023 Feb;158:360–4.
- 412 19. Bavato F, Cathomas F, Klaus F, Gütter K, Barro C, Maceski A, et al. Altered neuroaxonal
- integrity in schizophrenia and major depressive disorder assessed with neurofilament light
- chain in serum. Journal of Psychiatric Research. 2021 Aug;140:141–8.
- 20. Michel M, Fiebich BL, Kuzior H, Meixensberger S, Berger B, Maier S, et al. Increased
- 416 GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. Transl
- 417 Psychiatry. 2021 Jun;11(1):308.
- 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021
- 420 Mar 29;n71.
- 421 22. American Psychiatric Association, American Psychiatric Association. Diagnostic and
- statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC:
- 423 American Psychiatric Association; 2000. 943 p.
- 424 23. American Psychiatric Association, American Psychiatric Association, editors. Diagnostic
- and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American
- 426 Psychiatric Association; 2013. 947 p.

- 427 24. Sheehan DV. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The
- Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV
- and ICD-10. J Clin Psychiatry. 1998;
- 430 25. World Health Organization. International statistical classification of diseases and related
- health problems (11th ed.) [Internet]. 2019. Available from: https://icd.who.int/
- 432 26. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane
- Handbook for Systematic Reviews of Interventions [Internet]. 1st ed. Wiley; 2019 [cited
- 434 2024 Jan 12]. Available from:
- 435 https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604
- 436 27. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size,
- median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018 Jun;27(6):1785–
- 438 805.
- 439 28. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from
- the sample size, median, range and/or interquartile range. BMC Medical Research
- 441 Methodology. 2014 Dec 19;14(1):135.
- 442 29. Higgins J, Li T, Deeks J. Chapter 6: Choosing effect measures and computing estimates of
- effect [Internet]. Vol. Cochrane Handbook for Systematic Reviews of Interventions version
- 444 6.0. Cochrane; 2019 [cited 2023 Dec 24]. Available from:
- https://training.cochrane.org/handbook/current/chapter-06
- 30. Rohatgi A. WebPlotDigitizer [Internet]. Pacifica, California, USA; 2022 [cited 2023 Oct 31].
- 447 Available from: https://automeris.io/WebPlotDigitizer
- 31. Simrén J, Andreasson U, Gobom J, Suarez Calvet M, Borroni B, Gillberg C, et al.
- Establishment of reference values for plasma neurofilament light based on healthy
- individuals aged 5–90 years. Brain Communications. 2022 Jul 4;4(4):fcac174.
- 451 32. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle -Ottawa
- scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [Internet].
- 453 2011 [cited 2024 Jan 12]. Available from:
- http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- 455 33. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical
- 456 tutorial. Evid Based Mental Health. 2019 Nov;22(4):153–60.
- 457 34. Serrano-Castro PJ, Garzón-Maldonado FJ, Casado-Naranjo I, Ollero-Ortiz A, Mínguez-
- 458 Castellanos A, Iglesias-Espinosa M, et al. The cognitive and psychiatric subacute impairment
- in severe Covid-19. Sci Rep. 2022 Mar 3;12(1):3563.
- 460 35. Fernqvist A, Alexiou E, Zetterberg H, Howner K, Nilsson T, Andiné P. Plasma
- neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot
- 462 study. Front Psychiatry. 2023 May 4;14:1176266.

- 36. Zachrisson OCG, Balldin J, Ekman R, Naesh O, Rosengren L, Ågren H, et al. No evident
- neuronal damage after electroconvulsive therapy. Psychiatry Research. 2000 Oct;96(2):157–
- 465 65.
- 466 37. Ferensztajn-Rochowiak E, Tarnowski M, Samochowiec J, Michalak M, Ratajczak MZ,
- 467 Rybakowski JK. Increased mRNA expression of peripheral glial cell markers in bipolar
- disorder: The effect of long-term lithium treatment. European Neuropsychopharmacology.
- 469 2016 Sep;26(9):1516–21.
- 38. Poletaev AB, Morozov SG, Gnedenko BB, Zlunikin VM, Korzhenevskey DA. Serum Anti-
- 471 SlOOb, Anti-GFAP and Anti-NGF Autoantibodies of IgG Class in Healthy Persons and
- Patients with Mental and Neurological Disorders. Autoimmunity. 2000 Jan;32(1):33–8.
- 39. van Engelen MPE, Heijst H, Willemse EAJ, Oudega ML, Vermunt L, Scheltens P, et al.
- 474 Urine as matrix for analysis of neurofilament light chain is not suitable to distinguish
- frontotemporal dementia from psychiatric diseases. Brain Communications. 2023;5(2).
- 476 40. Wallensten J, Mobarrez F, Åsberg M, Borg K, Beser A, Wilczek A, et al. Isoforms of soluble
- vascular endothelial growth factor in stress-related mental disorders: a cross-sectional study.
- 478 Sci Rep. 2021 Aug 17;11(1):16693.
- 41. Katisko K, Cajanus A, Jääskeläinen O, Kontkanen A, Hartikainen P, Korhonen VE, et al.
- Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar
- degeneration and primary psychiatric disorders. J Neurol. 2020 Jan;267(1):162–7.
- 42. Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, et al. GFAP as a
- biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and
- prognostic performance. J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305–12.
- 485 43. Bai YM, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Procollagen type 1 N-
- 486 terminal propeptide, neurofilament light chain, proinflammatory cytokines, and cognitive
- function in bipolar and major depressive disorders: An exploratory study of brain–bone axis
- and systemic inflammation. Journal of Psychiatric Research. 2023 Feb;158:403–8.
- 489 44. Besse M, Belz M, Folsche T, Vogelgsang J, Methfessel I, Steinacker P, et al. Serum
- neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. The
- World Journal of Biological Psychiatry. 2020 Feb 7;21(2):148–54.
- 492 45. Chen MH, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Neurofilament light chain is
- a novel biomarker for major depression and related executive dysfunction. International
- Journal of Neuropsychopharmacology. 2022;25(2):99–105.
- 495 46. Jiang L, Shen Z, Cheng Y, Lu J, He B, Xu J, et al. Elevated serum neurofilament levels in
- 496 young first-episode and medication-naïve major depressive disorder patients with alterative
- white matter integrity. Psychiatry Research: Neuroimaging. 2021 Nov;317:111351.

498 47. Ramezani M, Simani L, Fard MG, Abbaszadeh F, Shadnia S. Increased levels of

neurofilament light chain in suicide attempters' serum. Translational Neuroscience. 2022

- 500 Aug 5;13(1):218–23.
- 48. Wallensten J, Mobarrez F, Åsberg M, Borg K, Beser A, Wilczek A, et al. Plasma levels of
- 502 S100B and neurofilament light chain protein in stress-related mental disorders. Sci Rep.
- 503 2022 May 18;12(1):8339.
- 49. Aggio V, Fabbella L, Finardi A, Mazza EB, Colombo C, Falini A, et al. Neurofilaments
- light: Possible biomarker of brain modifications in bipolar disorder. Journal of Affective
- 506 Disorders. 2022 Mar;300:243–8.
- 507 50. Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, et al.
- Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from
- behavioural variant frontotemporal dementia. Journal of Psychiatric Research.
- 510 2019;113(February):137–40.
- 51. Chen WY, Huang MC, Chiu CC, Cheng YC, Kuo CJ, Chen PY, et al. The interactions
- between vitamin D and neurofilament light chain levels on cognitive domains in bipolar
- disorder. BJPsych open. 2022 Nov;8(6):e207.
- 52. Rolstad S, Jakobsson J, Sellgren C, Ekman CJ, Blennow K, Zetterberg H, et al. Cognitive
- performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients
- with bipolar disorder and healthy controls. PloS one. 2015;10(5):e0127100–e0127100.
- 53. Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, et al. Serum
- neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in
- multiple sclerosis. Brain. 2018 Aug 1;141(8):2382–91.
- 520 54. Bridel C, Van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeño
- JC, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in
- Neurology: A Systematic Review and Meta-analysis. JAMA Neurology. 2019
- 523 Jun;76(9):1035–48.
- 524 55. Eratne D, Keem M, Lewis C, Kang M, Walterfang M, Farrand S, et al. Cerebrospinal fluid
- neurofilament light chain differentiates behavioural variant frontotemporal dementia
- progressors from non-progressors. Journal of the Neurological Sciences. 2022
- 527 Nov;442:120439.

530

- 56. Cuthbert BN. Research Domain Criteria (RDoC): Progress and Potential. Curr Dir Psychol
- 529 Sci. 2022 Apr 1;31(2):107–14.




Figure 1. PRISMA Diagram for study selection




Figure 2a. Forest plot of NfL in major depression (all studies)




Figure 2b. Forest plot of NfL in major depression (age-matched studies only)




Figure 2c. Forest plot of NfL in major depression (Simoa and CSF studies only)




Figure 2d. Forest plot of GFAP in major depression




Figure 3a. Forest plot of NfL in bipolar disorder (all studies)

| Study | Total | Bipolar Mean | disorder SD | Total | Mean | Control SD | Standardised Mean Difference | SMD | 95%-CI | Weight |
|---|------------------------|--------------------------------|--|------------|--------------------------------|---------------------------------------|---------------------------------|----------------------|---|---|
| Eratne et al. 2023 Knorr et al. 2022 Steinacker et al. 2021 Al Shweiki et al. 2019 Random effects model | 121 85 11 11 | 8.35 6.96 21.20 23.07 | 4.7600 3.0920 16.6000 15.8767 | 44 16 | 9.36 6.04 15.20 17.08 | 14.1500 2.5597 7.1000 8.7144 | | 0.31 0.49 0.52 | [-0.37; 0.17] [-0.05; 0.68] [-0.29; 1.27] [-0.19; 1.24] [-0.27; 0.68] | 14.9% 14.0% 9.4% 10.1% 48.5% |
| Heterogeneity: $I^2 = 48\%$, τ | $^{2} = 0.05$ | 517, p = 0 Blood E | | | | | | 5.25 | [0.2., 0.00] | 101070 |
| Bai et al. 2023 Ramezani et al. 2022 Random effects model Heterogeneity: $f^2 = 0\%$, τ^2 | 25 22 47 | 28.47 39.45 | 12.3859 32.1045 | | 16.74 13.72 | 6.8072 5.1094 | # # \$ | 1.25 | [0.60; 1.76] [0.67; 1.84] [0.76; 1.68] | 11.6% 11.6% 23.1% |
| Knorr et al. 2022 Rolstad et al. 2015 Random effects model Heterogeneity: $J^2 = 91\%$, τ | 85 82 167 | 485.73 | 175.7168 425.6200 | | 379.52 254.38 | 269.7610 55.4200 | | 0.73 | [-0.49; 0.24] [0.40; 1.06] [-5.12; 5.74] | 14.0% 14.4% 28.4% |
| Random effects model Prediction interval Heterogeneity: $I^2 = 82\%$, τ Test for subgroup difference | $x^2 = 0.22$ | | | 362 | | | -4 -2 0 2 4 | 0.50 | [0.06; 0.94] [-0.74; 1.74] | 100.0% |

Figure 3b. Forest plot of NfL in bipolar disorder (age-matched studies only)




Figure 3c. Forest plot of NfL in bipolar disorder (CSF and Simoa only)

Table 1. Characteristics of studies included: NfL in major depression

| Authors and year | Country | Sample Type | Analysis type | Diagnosis classification | Mood state | Sampl | e size | | age n (SD) | | Sex male %) | NfL conce | entration^ | Total NOS Score |
|---------------------------------|-------------|----------------|-------------------|--------------------------|--|-------|---------|--|--|------|----------------|--------------------------------------|--|-----------------------|
| | | | | | | Case | Control | Case | Control | Case | Control | Case | Control | |
| Ashton et al, 2021 (6) | England | Plasma | Simoa | DSM-5 | Not specified | 51 | 114 | 32.3 (6.9) | 64.0 (14.1) | 69% | 55% | 11.19 (5.8) | 22.5 (10.7) | 3 |
| Bai et al, 2023 (43) | Taiwan | Serum | HRP ELISA | DSM-5 | HDRS ≤16 | 24 | 29 | 30.8 (13.0) | 30.9 (10.7) | 67% | 62% | 22.4 (12.3)** | 16.7 (6.8) | 5 |
| Bavato et al, 2021 (19) | Switzerland | Plasma | Simoa | DSM-5 | Clinically stable | 41 | 258 | 36.0 (10.9) | Unavailable | 59% | NA% | 26.3 (10.4) | 24.5 (9.6) | 5 |
| Besse et al, 2020 (44) | Germany | Serum | Simoa | ICD-10 | Moderate to severe depressive episode | 15 | 15 | 49.2 (14.0) | "± 3 years" | 73% | NA% | 17.4 (11.88) | Mean = 15.57 95% CI*: 10.69, 20.40 | 5 |
| Chen et al, 2022 (45) | Taiwan | Plasma | HRP ELISA | DSM-5 | Not specified | 40 | 40 | 28.3 (14.4) | 28.3 (14.1) | 68% | 68% | 28.8 (22.5)** | 16.7 (8.1) | 5 |
| Eratne et al, 2023 (8) | Australia | Plasma | Simoa | DSM-IV | Depressive phase >= moderate severity | 42 | 96 | 55.0 (12.9) | 44.5 (14.4) | 57% | 52% | 10.9 (7.0)** | 9.4 (14.2)** | 4 |
| Gudmundsson et al, 2010 (14) | Sweden | CSF | ELISA Sandwich | DSM-III-R | Not specified | 11 | 65 | Combined: 7 | 3.9 (3.2) | 100% | 100% | 427 (318) | 277 (186) | 5 |
| Huang et al, 2023 (18) | Taiwan | Serum | Simoa | DSM-IV-TR | Outpatients | 35 | 86 | 34.7 (10.3) | 33.4 (6.2) | 77% | 13% | 5.4 (2.2) | 6.7 (2.7) | 5 |
| Hviid et al, 2023 (15) | Denmark | Serum | Simoa | DSM-IV | Treatment naive | 110 | 33 | 42 (11) | 39 (14) | 65% | 70% | 7.7 (3.0)* | 7.6 (3.1)* | 5 |
| Jiang et al 2021, (46) | China | Serum | ELISA Sandwich | DSM-IV | First episode, HDRS > 16 | 82 | 72 | 34 (11) | 34 (12) | 61% | 49% | Median = 405.8 IQR: 281.5-625.5 | Median = 143.5 IQR: 73.6–339.3 | 5 |
| Katisko et al, 2020 (41) | Finland | Serum | Simoa | ICD-10 | Included moderate, severe & psychotic depression | 16 | 0 | 55.7 (6.7) | NA | 56% | NA | 12.4 (4.3)** | NA | 3 |
| Ramezani et al, 2022 (47) | Iran | Serum | ELISA | DSM-5 | Suicide attempt | 28 | 35 | M: 26.28 (9.37) F: 26.61 (9.49) | M: 28.10 (8.54) F: 30.76 (5.12) | 75% | 71% | M: 55.42 (33.63) F: 36.66 (35.21) | M: 14.11 (4.38) F: 13.57 (5.45) | 5 |
| Steinacker et al, 2021 (17) | Germany | Serum | Simoa | DSM-5 | Moderate-severe depressive episode | 45 | 16 | Median=48 Range 19-69 | Median=45 Range 27-64 | 64% | 75% | 29.3 (35.3) | 15.2 (7.1) | 4 |
| Wallensten et al, 2022 (48) | Sweden | Plasma | ELISA | ICD-10 | Not specified | 31 | 61 | 40.3 (10.8) | 42.9 (9.5) | 84% | 85% | 357.4 (87.1) | 306.4 (115.7) | 6 |

[^]CSF = ng/L, plasma/serum = pg/mL; *estimates using WebPlotDigitzer; **data obtained directly from corresponding author
CI = confidence interval, F = females, HDRS = Hamilton Depression Rating Scale, M = males, MADRS = Montgomery-Asberg Depression Rating Scale, NA = not applicable, NOS = Newcastle-Ottawa Scale, YMRS = Young Mania Rating Scale

Table 2. Characteristics of studies included: NfL in bipolar disorder

| Authors and year | Country | Sample Type | Analysis type | Diagnosis classification | Mood state | Sampl | e size | Age Mean (SD) | | Sex nale %) | | NfL conc | entration^ | Total NOS Score |
|--------------------------------|-----------|--------------|------------------|--------------------------|--|-------|---------|--|---------------------------------------|----------------|---------|---|---|-----------------------|
| | | | | | | Case | Control | Case | Control | Case | Control | Case | Control | |
| Aggio et al, 2022 (49) | Italy | Plasma | Simoa | DSM-IV | Depressed | 45 | 29 | 48.2 (11.9) | 41.8 (10.2) | 78% | 55% | 9.1 (4.8) | 4.28 (2.39) | 3 |
| Al Shweiki et al, 2019 (50) | Germany | Serum | Simoa | DSM-5 | Manic, depressive and mixed states | 11 | 27 | Median = 51.4 IQR: 33.5-58.1 | Median = 46.8 IQR: 39.1-54.1 | 36% | 63% | Median = 17.8 IQR: 12.6 - 23.1 | Median = 17.8 IQR: 11.3 - 19.1 | 4 |
| Bai et al, 2023 (43) | Taiwan | Serum | HRP ELISA | DSM-5 | YMRS ≤12 | 25 | 29 | 33.2 (13.2) | 30.9 (10.7) | 60% | 62% | 28.5 (12.4)** | 16.7 (6.8) | 5 |
| Chen et al, 2022 (51) | Taiwan | Serum | Simoa | DSM-5 | Euthymic | 100 | | 46.5 (11.7) | NA | 52% | NA% | 11.1 (8.1)** | NA | 5 |
| Eratne et al, 2023 (8) | Australia | Plasma | Simoa | DSM-IV | Depressive phase of at least moderate severity | 121 | 96 | 44.1 (12.18) | 44.48 (14.35) | 62% | 52% | 8.4 (4.8)** | 9.4 (14.2)** | 5 |
| Knorr et al, 2022 (16) | Denmark | CSF & Plasma | ELISA & Simoa | ICD-10 | In remission (YMRS <=8; HDRS <= | 85 | 44 | Median = 33 IQR: 26-42 | Median = 30 IQR: 25-42 | 51% | 52% | CSF: Median = 332 IQR: 246-479 Plasma: | CSF: Median = 354 IQR: 214-566 Plasma: | 6 |
| | | | | | 8) HDR2 <= | | | | | | | Median = 6.81 IQR: 4.97 - 9.07 | Median = 5.73 IQR: 4.50 - 7.84 | |
| Ramezani et al, 2022 (47) | Iran | Serum | ELISA | DSM-5 | Suicide attempt | 22 | 35 | M: 33.00 (15.18) F: 31.72 (13.10) | M: 28.10 (8.54) F: 30.76 (5.12) | 82% | 71% | M: 46.50 (38.27) F: 37.88 (31.63) | | 5 |
| Rolstad et al, 2015 (52) | Sweden | CSF | ELISA | DSM-IV | Euthymic (MADRS < 14, YMRS < 14) | 82 | 71 | 38.3 (12.5) | 37.8 (14.6) | 59% | 62% | 485.7 (425.6) | 254.4 (55.4) | 5 |
| Steinacker et al, 2021 (17) | Germany | Serum | Simoa | DSM-5 | Manic, depressive and mixed states | 11 | 16 | Median = 48 Range: 19-69 | Median = 45 Range: 27-64 | 27% | 75% | 21.2 (16.6) | 15.2 (7.1) | 4 |

[^]CSF = ng/L, plasma/serum = pg/mL; *estimates using WebPlotDigitzer; **data obtained directly from corresponding author
CI = confidence interval, F = females, HDRS = Hamilton Depression Rating Scale, M = males, MADRS = Montgomery-Asberg Depression Rating Scale, NA = not applicable, NOS = Newcastle-Ottawa Scale, YMRS = Young Mania Rating Scale

Table 3. Characteristics of studies included: GFAP in major depression and bipolar disorder

| Author | Country | Country Sample Analysis Diagnosis Mood state Sample size Age Type type classification Mood state Sample size Mean (SD) | | = | | Sex ale %) | GFAP concentration [^] | | Total NOS Score | | | | | |
|---------------------------------|---------|--|-------------------|-----------|--|---------------|---------------------------------|----------------------------|----------------------------|------|---------|--------------|---------------|---|
| | | | | | | Case | Control | Case | Control | Case | Control | Case | Control | |
| Major depressive disc | rder | | | | | | | | | | | | | |
| Gudmundsson et al, 2010 (14) | Sweden | CSF | ELISA Sandwich | DSM-III-R | Not specified | 11 | 65 | Cases + contr | rols: 73.9 (3.2) | 100% | 100% | 946 (196) | 887 (308) | 5 |
| Hviid et al, 2023 (15) | Denmark | Serum | Simoa | DSM-IV | Treatment naïve | 110 | 33 | 42 (11) | 39 (14) | 65% | 70% | 63.7 (23.8)* | 74.2 (35.2)* | 5 |
| Katisko et al, 2021 (42) | Finland | Serum | Simoa | ICD-10 | Included moderate, severe and psychotic depression | 22 | 0 | 55.7 (6.3) | NA | 55% | NA | 224 (113)** | NA | 3 |
| Michel et al, 2021 (20) | Germany | CSF | ELISA | ICD-10 | Inpatients | 102 | 39 | 44.2 (13.6) | 34.6 (12.0) | 54% | 85% | 733 (401) | 245.6 (176.3) | 5 |
| Steinacker et al, 2021 (17) | Germany | Serum | Simoa | DSM-5 | Moderate- severe depressive episode | 45 | 16 | Median = 48 Range 19-69 | Median = 45 Range 27-64 | 64% | 75% | 211 (99) | 147.0 (61.0) | 4 |
| Bipolar disorder | | | | | | | | | | | | | | |
| Steinacker et al, 2021 (17) | Germany | Serum | Simoa | DSM-5 | Manic, depressive and mixed states | 11 | 16 | Median = 48 Range 19-69 | Median = 45 Range 27-64 | 27% | 75% | 125 (50) | 147.0 (61.0) | 4 |

 $^{^{\}wedge}$ CSF = ng/L, plasma/serum = pg/mL; *estimates using WebPlotDigitzer; **unpublished data obtained directly from corresponding author F = females, M = males, NA = not applicable, NOS = Newcastle-Ottawa Scale

eMethods - Search strategy for respective databases

Database: Ovid MEDLINE(R): inception to June 27, 2023

Search Strategy:

- 1. Affective Symptoms/ or exp Catatonia/ or exp Depression/ or exp Mental Fatigue/ or exp Mood Disorders/ or exp Anxiety/ or exp Anxiety Disorders/ or Mania/ or Depression, Chemical/ or Cognitive Dysfunction/ or depress*.mp. or bipolar*.mp. or anxiety*.mp. or *Mental Disorders/ or psychiatric disorder*.mp. (1080981)
- 2. Glial Fibrillary Acidic Protein/ or Neurofilament Proteins/ (22084)
- 3. (neurofilament light* or glial fibrillary acidic protein*).mp. (27935)
- 4. 2 or 3 (32209)
- 5. 1 and 4 (1445)
- 6. (5 not rats not animals/) or (5 and humans/) (656)

Database: Web of Science Search Strategy: inception to June 27, 2023

Searches:

- 1: TS=(bipolar*) OR TS=(mania*) OR TS=(depressi*) OR TS=(anxiety*) OR TS=(psychiatr* disord*) OR TS=(mental disorder*) 1230138
- 2: TS=(neurofilament*) OR TS=(Glial fibrillary acidic protein*) OR TS=(NF-L) OR TS=(GFAP) 40397
- 3: #1 AND #2 and Article or Early Access or Proceeding Paper or Data Paper or Note or Letter (Document Types) 1554

Embase search: incepetion to May 31 2023

- 1. exp glial fibrillary acidic protein/ 36983
- 2 exp neurofilament/ or exp neurofilament protein/ 19626
 medRxiv preprint doi: https://doi.org/10.14.01/2024.03.07.24303938; this version posted March 9, 2024. The copyright holder for this preprint
 (whick past expression to preserve evice) Is disconder/10.096 (who has granted medRxiv a license to display the preprint in perpetuity.

 4. exp bipolar depression/ or exp bipolar disorder/ or exp manual 96498

 - 5. exp anxiety/ or exp anxiety assessment/ or exp anxiety disorder/ 611058
 - 6. 1 or 2 53764
 - 7. 3 or 4 or 5 1070529
 - 8. 6 and 7 1554
 - 9. limit 8 to human 809

Pubmed: incepetion to May 31 2023

((bipolar* OR depress* OR anxie*)) AND (neurofilament light* OR glial fibrillary acidic protein*) 1059 hits

PSYCHInfo: Inception to May 31 2023

- (Neurofilaments or neurofilament protein L or Neurofilament Proteins or Glial Fibrillary Acidic Protein or (neurofilament light* or glial fibrillary acidic protein*)).mp. (4714)
- exp Chronic Fatigue Syndrome/ or exp Chronic Mental Illness/ or exp Affective Disorders/ or exp Anxiety Disorders/ or exp Bipolar Disorder/ or exp Chronic Mental Illness/ or exp Affective Psychosis/ or exp Acute Stress Disorder/ or exp Adjustment Disorders/ or exp Prolonged Grief Disorder/ or exp Fatigue/ or exp Psychiatric Symptoms/ or exp Treatment Resistant Disorders/ or exp Treatment Resistant Depression/ or exp Atypical Depression/ or exp Acute Stress Disorder/ or depress*.mp. or bipolar*.mp. or anxiety*.mp. or psychiatric disorder*.mp. or mental disorder*.mp. (779119)
- 1 and 2 (372)
 - 4 limit 7 to human (150)

eTable 1 - Newcastle-Ottawa Scale scores for the included studies

| Study Author | Selection - Representativeness of the cohort - Sample size justification - Ascertainment of mood or anxiety disorder | Comparability - Controls for age between case and controls - Controls for additional covariates (sex, weight, BMI, renal function) between cases and controls | Outcome - Validated measure of biomarker - Appropriate statistical analysis which is well described | Total |
|--|---|---|---|-------|
| Aggio et al, 2022 (1) | 1 | 0 | 2 | 3 |
| Al Shweiki et al, 2019 (2) | 1 | 1 | 2 | 4 |
| Ashton et al, 2021 (3) | 1 | 0 | 2 | 3 |
| Bai et al, 2023 (4) | 1 | 2 | 2 | 5 |
| Bavato et al, 2021 (5) | 1 | 2 | 2 | 5 |
| Besse et al, 2020 (6) | 1 | 2 | 2 | 5 |
| Chen et al, 2022b (7) | 1 | 2 | 2 | 5 |
| Chen et al. 2022a (8) | 1 | 2 | 2 | 5 |
| edRxiv preprint doi: https://doi.org/10.1 (whildir:waia@o@b@tlified(by/pee /)evi | 101/2024.03.07.24303938; this version piew) is the author/fullder, who has grante made available under a CC-BY-ND 4.0 I | osted March 9, 2024. The copyright holder for this prep d medRxiv a license to display the preprint in perpetuity nternational license. | rint v. 2 | 5 |
| Eratne et al, 2023 (9) (depression) | 1 | 1 | 2 | 4 |
| Gudmundsson et al, 2010 (10) | 1 | 2 | 2 | 5 |
| Huang et al, 2023 (11) | 1 | 2 | 2 | 5 |
| Hviid et al, 2023 (12) | 1 | 2 | 2 | 5 |
| Jiang et al 2021, (13) | 1 | 2 | 2 | 5 |
| Katisko et al, 2020 (14) | 1 | 0 | 2 | 3 |
| Katisko et al, 2021 (15) | 1 | 0 | 2 | 3 |
| Knorr et al, 2022 (16) | 3 | 2 | 1 | 6 |
| Michel et al, 2021 (17) | 1 | 2 | 2 | 5 |
| Ramezani et al, 2022 (18) | 1 | 2 | 2 | 5 |
| Rolstad et al, 2015 (19) | 1 | 2 | 2 | 5 |
| Steinacker et al, 2021 (20) | 1 | 1 | 2 | 4 |
| Wallensten et al, 2022 (21) | 2 | 2 | 2 | 6 |


eReferences

- 1. Aggio V, Fabbella L, Finardi A, Mazza EB, Colombo C, Falini A, et al. Neurofilaments light: Possible biomarker of brain modifications in bipolar disorder. Journal of Affective Disorders. 2022 Mar;300:243–8.
- 2. Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research. 2019;113(February):137–40.
- 3. Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021 Jun 7;12(1):3400.
- 4. Bai YM, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Procollagen type 1 N-terminal propeptide, neurofilament light chain, proinflammatory cytokines, and cognitive function in bipolar and major depressive disorders: An exploratory study of brain–bone axis and systemic inflammation. Journal of Psychiatric Research. 2023 Feb;158:403–8.
- 5. Bavato F, Cathomas F, Klaus F, Gütter K, Barro C, Maceski A, et al. Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. Journal of Psychiatric Research. 2021 Aug;140:141–8.
- 6. Besse M, Belz M, Folsche T, Vogelgsang J, Methfessel I, Steinacker P, et al. Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. The World Journal of Biological Psychiatry. 2020 Feb 7;21(2):148–54.
- 7. Chen WY, Huang MC, Chiu CC, Cheng YC, Kuo CJ, Chen PY, et al. The interactions between vitamin D and neurofilament light chain levels on cognitive domains in bipolar disorder. BJPsych open. 2022 Nov;8(6):e207.

- 8. Chen MH, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Neurofilament light chain is a novel biomarker for major depression and related executive dysfunction. International Journal of Neuropsychopharmacology. 2022;25(2):99–105.
- 9. Eratne D, Kang M, Malpas C, Simpson-Yap S, Lewis C, Dang C, et al. Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders. Aust N Z J Psychiatry. 2023 Jul 21;00048674231187312.
- 10. Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, et al. Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Research. 2010;176(2–3):174–8.
- 11. Huang MC, Chen CH, Liu TH, Chung AN, Liu YL, Quednow BB, et al. Comorbidity of ketamine dependence with major depressive disorder increases the vulnerability to neuroaxonal pathology. Journal of Psychiatric Research. 2023 Feb;158:360–4.
- 12. Hviid CVB, Benros ME, Krogh J, Nordentoft M, Christensen SH. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression. Journal of Affective Disorders. 2023 Oct 1;338:341–8.
- 13. Jiang L, Shen Z, Cheng Y, Lu J, He B, Xu J, et al. Elevated serum neurofilament levels in young first-episode and medication-naïve major depressive disorder patients with alterative white matter integrity. Psychiatry Research: Neuroimaging. 2021 Nov;317:111351.
- 14. Katisko K, Cajanus A, Jääskeläinen O, Kontkanen A, Hartikainen P, Korhonen VE, et al. Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol. 2020 Jan;267(1):162–7.
- 15. Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, et al. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305–12.
- medRxiv preprint doi: https://doi.org/10.1101/2024.03.07.24303938; this version posted March 9, 2024. The copyright holder for this preprint
 (Վիճրիկաթորվեց Ֆիտրիկաթորվեց Ֆիտրիկաթորվեց Արտիայան Արտիայա
 - 17. Michel M, Fiebich BL, Kuzior H, Meixensberger S, Berger B, Maier S, et al. Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. Transl Psychiatry. 2021 Jun;11(1):308.
 - 18. Ramezani M, Simani L, Fard MG, Abbaszadeh F, Shadnia S. Increased levels of neurofilament light chain in suicide attempters' serum. Translational Neuroscience. 2022 Aug 5;13(1):218–23.
 - 19. Rolstad S, Jakobsson J, Sellgren C, Ekman CJ, Blennow K, Zetterberg H, et al. Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. PloS one. 2015;10(5):e0127100–e0127100.
 - 20. Steinacker P, Al Shweiki MR, Oeckl P, Graf H, Ludolph AC, Schönfeldt-Lecuona C, et al. Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research. 2021 Dec;144:54–8.
 - 21. Wallensten J, Mobarrez F, Åsberg M, Borg K, Beser A, Wilczek A, et al. Plasma levels of S100B and neurofilament light chain protein in stress-related mental disorders. Sci Rep. 2022 May 18;12(1):8339.

sFigure 1 - Funnel plots


a. NfL in major depression




medRxiv preprint doi: https://doi.org/10.1101/2024.03.07.24303938; this version posted March 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 international license.

1.5

b. GFAP in major depression



c. NfL in bipolar disorder



medRxiv preprint doi: https://doi.org/10.1101/2024.03.07.24303938; this version posted March 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.



PRISMA 2020 Checklist

| <u>e</u> | | | |
|--|-----------|--|---------------------------------------|
| Section and Topic | Item # | Checklist item | Location where item is reported |
| TITLE | I | | |
| Title | 1 | Identify the report as a systematic review. | Pg 1 |
| ABSTRACT | ı | | |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | Pg 4-5 |
| INTRODUCTION | l . | | |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | Pg 6/line 89 |
| bjectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | Pg 7/line 133 |
| mETHODS | ı | | |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | Pg 7/line 144 |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Pg 8/line 156 |
| search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | Supplementar |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | Pg 8/line 164 |
| a collection | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Pg 8/line 171 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | Pg 8/line 171 |
| vailable | 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | Pg 8/line 171 |
| र्ज किtudy risk of bias खंडिंड खंडिंड के किंग्रेस | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Pg 9/line 185 |
| .⊈ffect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | Pg 8/line 171 |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | Pg 7/line 186 |
| h d pa | 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | Pg 8/line 173 |
| 9 | 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Pg 9/line 182 |
| not ce | 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Pg 9/line 182 |
| was no | 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | Pg 9/line 205 |
| ्रेपू | 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | Pg 9/line 205 |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | Pg 10/line 221 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Pg 9/line 201 |



PRISMA 2020 Checklist

| Section and Topic | Item # | Checklist item | Location where item is reported |
|--|-----------|--|---------------------------------------|
| RESULTS | | | |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | Figure 1 |
| | 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | Pg 10/line 2 |
| Study characteristics | 17 | Cite each included study and present its characteristics. | Table 1-2 |
| Risk of bias in | 18 | Present assessments of risk of bias for each included study. | Supplement eTable 1 |
| Results of Individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | Pg 11/line 2 Figures 2-3 |
| Results of | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | Supplemen eTable 1 |
| Syntheses | 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Pg 11/line |
| Ω Ż | 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Pg 11/line |
| ≻ | 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | Pg 11/line |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | Supplemer eFigure 1 |
| Certainty of Evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | Pg 11/line |
| DISCUSSION | | | |
| iscussion | 23a | Provide a general interpretation of the results in the context of other evidence. | Pg 13/line |
| ade avage as a second as a sec | 23b | Discuss any limitations of the evidence included in the review. | Pg 14/line |
| ade | 23c | Discuss any limitations of the review processes used. | Pg 14/line |
| E 8 | 23d | Discuss implications of the results for practice, policy, and future research. | Pg 15/line |
| *OTHER INFORMA | TION | | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | Pg 7/line 1 |
| protocor | 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | Pg 7/line 1 |
| | 24c | Describe and explain any amendments to information provided at registration or in the protocol. | N/A |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | Pg 2/line 1 |
| Competing interests | 26 | Declare any competing interests of review authors. | Pg 2/line 2 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | N/A |

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71 Pg 8/line 193

For more information, visit: http://www.prisma-statement.org/